The breast cancer market, characterized by high incidence and long treatment durations, represents a great commercial opportunity for drug developers. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio/Verzenios/Virginio) are creating new dynamics in the metastatic HR-positive/HER2-negative treatment practice. In HER2-positive breast cancer, HER2-targeting drugs in development are forecast to enter the market, while sales of current HER2-targeting agents will be impacted as a result of competition, label expansions, biosimilar entries, and new trials leading to changes in treatment guidelines. Furthermore, the approval of PARP inhibitors (AstraZeneca’s Lynparza and Pfizer’s Talzenna), PD-1-targeting agents (Roche/Genentech/Chugai’s Tecentriq), PI3K inhibitors (Novartis’s Piqray), HER2-targeting agents (Daiichi Sankyo/AstraZeneca’s Enhertu and Seattle Genetics’ Tukysa), TROP2-targeting antibody-drug conjugates (Immunomedics’ Trodelvy), and the anticipated entry of other agents from these drug classes will diversify treatment options, especially for triple-negative breast cancer.

Questions answered

  • What is the size of the drug-treatable breast cancer population, and how will drug-treatment rates change over time?
  • What is the expected market impact of recent drug approvals, such as Tecentriq, Piqray, Enhertu, Tukysa, and Trodelvy on the various subpopulations of breast cancer?
  • What are the most promising agents in the pipeline, and how will they shape the future of the breast cancer market?
  • What are the drivers and constraints in the breast cancer market, and how will the market evolve over the forecast period?

Contents Highlights

  • Geographies: United States, EU5, Japan
  • Primary Research: 19 country-specific interviews with thought-leading medical oncologists supported by survey data collected for this and other DRG research
  • Epidemiology: Incidence of breast cancer by country, segmented by HR and HER2 status, staging, and line of therapy
  • Forecast: 10-year, annualized, drug-level sales and patient share of key breast cancer therapies through 2029, segmented by brands/generics and market-relevant drug-treatable populations
  •  Emerging Therapies: Phase III/PR: 16 drugs; coverage of select Phase I and II products

Product Description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • COVID-19
    • Key Findings
      • Breast Cancer - Key Findings - May 2020
    • Key Updates
      • May 2020
      • March 2020
      • December 2019
      • September 2019
      • June 2019
    • Market Outlook
      • Key Findings
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Breast Cancer?
        • What Factors Are Constraining the Market for Breast Cancer?
      • Segment-Specific Trends
        • Adjuvant and Neoadjuvant Market
        • First-Line Market
        • Second- and Subsequent-Line Market
    • Forecast
      • Market Forecast Downloads
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Disease Overview
      • Disease Pathophysiology
        • Prognostic Biomarkers
        • Patterns of Metastasis
      • Staging and Classification
        • Staging of Breast Cancer
      • Prognostic Gene Expression Signatures
        • Oncotype Dx
        • MammaPrint
        • The Quest H:I Ratio Test
      • Key Pathways and Drug Targets
        • Key Pathways and Drug Targets for Breast Cancer
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Diagnosed Incident Cases
        • Molecular Subtype
        • Stage at Diagnosis
        • Menopausal Status
        • Drug-Treatable Populations
        • Drug-Treated Populations
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • HER2-Targeted Agents
        • CDK4/6 Inhibitors
        • mTOR Pathway Inhibitors
        • Angiogenesis Inhibitors
        • Cytotoxic Agents
        • SERDs
        • PARP Inhibitors
        • Immune Checkpoint Inhibitors
        • PI3K Inhibitors
      • Medical Practice
        • Neoadjuvant Treatment of Stage II/III Breast Cancer
        • Adjuvant Treatment of Stage I-III Breast Cancer
        • First-Line Treatment of Advanced/Metastatic Breast Cancer
        • Second- and Subsequent-Line Treatment of Advanced/Metastatic Breast Cancer
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Breast Cancer
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • PARP Inhibitors
        • PI3K/AKT/mTOR Pathway Inhibitors
        • Immune Checkpoint Inhibitors
        • HER2/EGFR-Targeting Agents
        • Cytotoxic Agents
        • HDAC Inhibitors
        • Cancer Vaccines
        • CXCR4 Inhibitors
        • SERDs
        • SERMs
      • Early-Phase Pipeline Analysis
    • Access and Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug- and Regimen-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Dosing, Cycles of Therapy, and Compliance
        • Generic Erosion
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Breast Cancer Bibliography

Author(s): Paul Wilcock. PhD; Alexandre Vo Dupuy (PhamD, MSc)

Since October 2015, Dr. Wilcock has been a Business Insights Analyst in the oncology team at Decision Resources Group. He has experience in various indications including metastatic malignant melanoma and renal cell carcinoma, and will have a major focus on gastric cancer going forward. Previously, Dr. Wilcock was a Research Funding Manager at Cancer Research UK, where he developed a deep understanding of drug discovery, predominantly in the academic setting. He gained his doctorate from the University of Manchester where he utilized Systems Biology to explore the role of cell signaling and hypoxia in oral cancer.

Alexandre joined Decision Resources Group in 2017 as an Associate Epidemiologist. He holds a PharmD from Paris Descartes University as well as a Master in pharmacoepidemiology from the University of Bordeaux.   Prior to joining Decision Resources Group, he worked within the fields of Consulting and Real World Evidence ,   and as an intern within the Global Epidemiology department of   one of the top pharmaceutical company . As an associate epidemiologist, Alexandre works across multiple disease areas estimating and forecasting incidence and prevalence, with a focus on cancer epidemiology.

Related Reports

Breast Cancer | Current Treatment | Detailed, Expanded Analysis (US)

Hormone receptor (HR)-positive / HER2-negative breast cancer is the most prevalent breast cancer subtype. Treatment decisions are influenced by disease stage, genetic test score, menopausal statu...

View Details

Breast Cancer | Current Treatment | Detailed, Expanded Analysis: Treatment Sequencing (US)

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.

View Details

Breast Cancer | Unmet Need | Detailed, Expanded Analysis (US & EU ) Metastatic HR-Positive/ HER2-Negative

Despite the number of therapy options available, advanced or metastatic HR-positive / HER2-nega...

View Details

Breast Cancer | Geographic Focus - China | Breast Cancer | China In-Depth | China

COMING SOON Breast cancer is one of the most frequently diagnosed cancers among Chinese women. A high incidence and a prolonged treatment duration makes breast cancer a...

View Details